Document Detail


Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder.
MedLine Citation:
PMID:  23330767     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the growth and pubertal attainment of boys with attention deficit hyperactivity disorder (ADHD) on stimulant medication.
DESIGN, SETTING AND PARTICIPANTS: Longitudinal study of boys aged 12.00-15.99 2013s at recruitment in 2005-2011, with stimulant-treated ADHD for at least 3 2013s, attending three paediatric practices (subjects), compared with longitudinal data from 174 boys from the Nepean longitudinal study (controls).
MAIN OUTCOME MEASURES: Subjects' growth parameters before treatment were compared with controls aged 7 or 8 2013s; growth parameters and longitudinal changes on treatment to ages 12.00-13.99 and 14.00-15.99 2013s were compared with controls reviewed at 13 and 15 2013s of age, respectively. The subjects' pubertal staging and height velocity were related to their treatment history.
RESULTS: Sixty-five subjects were recruited; mean duration of treatment was 6.3 ± 1.9 2013s. At baseline, their growth parameters were not significantly different from those of the controls after adjusting for age. Compared with the controls, after adjusting for current age and baseline growth parameter z score, subjects aged 12.00-13.99 2013s had significantly lower weight and body mass index (P < 0.01), and those aged 14.00-15.99 2013s had significantly lower height and weight (P < 0.05). At 12.00-13.99 2013s of age, the subjects were comparable to the controls in their pubertal development adjusted for age, but those aged 14.00-15.99 2013s reported significant delay (mean Tanner stage, 3.6 for subjects v 4.0 for controls; P < 0.05). The dose of medication was inversely correlated with the height velocity from baseline to 14.00-15.99 2013s of age (P < 0.05).
CONCLUSIONS: Prolonged treatment (more than 3 2013s) with stimulant medication was associated with a slower rate of physical development during puberty. To maintain adequate height velocity during puberty, we recommend keeping the dose as low as possible.
Authors:
Alison S Poulton; Elaine Melzer; Paul R Tait; Sarah P Garnett; Chris T Cowell; Louise A Baur; Simon Clarke
Related Documents :
17314727 - Cannabis and anxiety and depression in young adults: a large prospective study.
22956867 - Testosterone replacement therapy among elderly males: the testim registry in the us (tr...
9460837 - Use of minor tranquilizers among norwegian physicians. a nation-wide comparative study.
19010657 - A profile of adolescent cocaine use in northern ireland.
22551657 - Interaction between age and aerobic fitness in determining heart rate dynamics.
20488887 - Midlife psychological stress and risk of dementia: a 35-year longitudinal population st...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Medical journal of Australia     Volume:  198     ISSN:  1326-5377     ISO Abbreviation:  Med. J. Aust.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400714     Medline TA:  Med J Aust     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  29-32     Citation Subset:  IM    
Affiliation:
Sydney Medical School Nepean, University of Sydney, Sydney, NSW, Australia. alison.poulton@sydney.edu.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  National Heart Foundation of Australia consensus statement on catheter ablation as a therapy for atr...
Next Document:  Male reproductive health disorders among Aboriginal and Torres Strait Islander men: a hidden problem...